South Africa’s Cannabis Crossroads: Medical Exports Rise While Inclusive Commercialisation Still Lags

Primary reference point: Cannabiz Africa industry reporting (2026)

https://www.cannabiz-africa.com/blog/6aab0d1806128bc82ed9c2b6?

Supporting sources: Department of Trade, Industry and Competition progress updates; SAHPRA licensing data; Karoo Bioscience coverage; Mayet & Associates compliance analysis; BusinessTech / draft private-use regulations reporting; Daily Maverick hemp sector features; earlier Prince litigation context.

South Africa’s cannabis sector in 2026 presents two parallel realities. On one track, licensed medical cannabis companies are investing hundreds of millions of rand, creating rural jobs, and steadily increasing exports of high-THC flower to Germany, Australia, the United Kingdom and other regulated markets. On the other track, the broader promise of an inclusive, job-rich cannabis economy that brings traditional growers, small-scale farmers and ordinary adult consumers into the formal system remains largely unfulfilled.

The gap between these two realities is the defining story of the moment.

The Medical Export Success Story

Facilities such as Karoo Bioscience’s operation in Vanrhynsdorp illustrate what is possible under the current SAHPRA-led medical pathway. The company has invested approximately R400 million in a state-of-the-art, solar-powered cultivation and processing site. It has become the largest single employer in the town, creating more than 100 permanent jobs and introducing an equity scheme that gives permanent staff a direct stake in the business. Senior government figures, including representatives from the Presidency, have publicly praised the project as an example of how medicinal cannabis can support rural economic development and position South Africa within global supply chains.

Similar licensed operators across the country are contributing to rising export volumes. South African flower is now a recognised origin in several of the world’s most demanding medical markets. The combination of favourable climate, improving compliance capacity, and relatively competitive production costs has allowed a small cohort of SAHPRA-licensed companies to establish a foothold.

This is real progress. It demonstrates that South Africa can meet international quality standards and that cannabis cultivation can generate formal employment in areas that need it.

The Missing Commercial Layer

What the medical track does not do is open the domestic adult-use market or create accessible pathways for the tens of thousands of traditional and small-scale growers who have cultivated the plant for generations. The Cannabis for Private Purposes Act 7 of 2024 removed the criminal prohibition on private adult use and cultivation, but it does not create a licensing system for commercial sale. Draft regulations published in early 2026 began to put numbers to private possession and cultivation limits (including the widely discussed 750 g figure), yet the Act itself still awaits full operationalisation and the commercial framework remains under development.

Government timelines shared through the Department of Trade, Industry and Competition point to a Hemp and Cannabis Commercialisation Policy targeted for Cabinet consideration and an overarching Cannabis Bill expected in Parliament by mid-2027. Until those instruments land and are implemented, the only fully legal commercial channels remain medical (SAHPRA) and industrial hemp (now operating under a higher 2 % THC threshold and agricultural permitting).

The result is a structural exclusion. Legacy growers in places such as Mpondoland, the rural Eastern Cape, and other traditional producing regions continue to operate outside the formal economy. Many face ongoing enforcement risk even as licensed facilities nearby export product at premium prices. Community organisations and litigants, including the ongoing Prince matter, have repeatedly highlighted this contradiction: a constitutional right to private use exists, yet the practical ability to obtain cannabis lawfully or to participate in the emerging industry does not.

Hemp’s Separate Trajectory

Industrial hemp has moved faster on the agricultural side. The raising of the THC threshold to 2 % and the issuance of well over a thousand cultivation permits have created space for fibre, grain and dual-purpose crops. Local breeding efforts, including work linked to Agricultural Research Council varieties, aim to reduce dependence on imported seed and to develop genetics suited to South African conditions. Start-ups focused on textiles and value-added hemp products are beginning to demonstrate commercial potential, although challenges around processing infrastructure, market access and consistent seed supply remain.

Hemp’s progress is encouraging, but it does not solve the high-THC inclusion problem. The two crops are regulated differently and serve different markets. Treating hemp success as a substitute for adult-use and traditional-grower reform misses the distinct social and economic claims attached to the psychoactive plant.

The Human and Social Cost of the Gap

Behind the policy timelines and investment figures sit real communities. Small-scale farmers who have grown dagga for decades watch licensed operations receive political praise and export revenue while their own activities remain precarious. Urban consumers navigate a grey market of clubs, delivery services and informal supply because no legal retail channel exists. Patients who cannot access or afford the formal medical system continue to rely on unregulated sources.

Enforcement continues unevenly. Large seizures of informal consignments are regularly reported, while the medical export sector operates with increasing confidence. The message received on the ground is that capital and compliance capacity determine who may participate, not historical connection to the plant or constitutional privacy rights.

What Inclusive Reform Would Require

A coherent next phase would need to address several linked issues simultaneously:

•  Clear, accessible licensing pathways for domestic adult-use cultivation, processing and retail that are not limited to high-capital pharmaceutical models.

•  Transitional arrangements and support for traditional and small-scale growers so they can enter the formal economy rather than being displaced by it.

•  Finalisation of private-use regulations so that the boundaries of lawful personal cultivation and possession are transparent.

•  Alignment of enforcement practice with the constitutional baseline established in 2018.

•  Continued growth of the medical export sector without allowing it to become the sole definition of “success.”

None of these steps is simple. Quality control, tax collection, youth protection and international treaty considerations all require careful design. The alternative, however, is the continuation of a two-tier system that generates export earnings for a few while leaving the majority of historical participants and ordinary consumers in legal and economic limbo.

Looking Ahead

The medical cannabis successes of 2025 and 2026 prove that South Africa can build competitive, compliant operations. The slow movement of commercialisation policy and the persistence of the Prince litigation and community demands prove that technical success is not the same as social legitimacy.

Until the commercial framework catches up with the constitutional and historical reality of cannabis in South Africa, the sector will remain divided: polished export facilities on one side, unresolved questions of justice and inclusion on the other. Bridging that divide is the central task of the next phase of reform.

The plant has already moved. The law and the institutions that govern it are still catching up